Microbot Medical Inc (MBOT) — Institutional Investor Activity (Q2 2026)

MBOT ranks #5264 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

74 institutions disclose a position in MBOT, but none treat it as a major bet — even AlphaCentric Advisors LLC, its most concentrated holder, allocates just 0.4% of its own portfolio to it.

Caitong International Asset Management Co., Ltd has trimmed its MBOT position for two straight quarters, cutting it by $86.4K while still holding $18.0.

MBOT is down 2.7% today, but institutions show net buying of $1.2M this quarter — a divergence between today's price move and the underlying institutional flow.

MBOT reported a net loss of $16.3M over the trailing twelve months.

• Not yet profitable — net loss of $16.3M over the trailing twelve months
• Revenue declined 88.2% year over year
• Net income declined year over year, from -$12.7M to -$16.3M
• Operating cash flow was negative, using $13.0M in cash
• Current ratio of 23.33x — enough short-term assets to cover short-term liabilities
• Liabilities run 5.94x equity — a highly leveraged balance sheet worth noting